Would you give T-DXd to patients with resolved drug-induced ILD from other agents such as prior chemo/targeted therapy/immunotherapy?

Topics: Breast Cancer • Medical Oncology • Interstitial lung disease • Pulmonology • Breast Cancer, Metastatic • HER2-low

Answer from: Medical Oncologist at Community Practice

Depending on the pathophysiology and prior offending agent, I would consider treating such patients with TDxd. Ado-trastuzumab emtansine has been rarely associated with ILD; in this particular case, ILD caused by another HER2-targeting ADC, unless it was grade 1, I may not consider challenging the p...

Comments

Medical Oncologist at Colorado Permanente Medical Group Hematology & Oncology
Could you comment on whether you would ever consid...

Medical Oncologist at University of Utah
In this case, we will have to weigh the risk benef...

at Yale Pulmonary And Critical Care
From a pulmonary perspective, I cautiously agree w...

Answer from: Medical Oncologist at Community Practice

The use of T-DXd in patients with resolved drug-induced Interstitial Lung Disease (ILD) from prior treatments should be carefully considered as T-DXd has been associated with ILD. The prescription information includes a warning about this risk. Hence, the decision to use T-DXd in such cases should b...

Related Questions